Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James D Berry

Showing results (61-70 of 176) with videos related to

Pageof 18
Sort By:
JAMA Neurology|September 11, 2023
Efficacy and Safety of Ravulizumab, a Complement C5 Inhibitor, in Adults With Amyotrophic Lateral Sclerosis: A Randomized Clinical TrialAngela Genge, Leonard H van den Berg, Glen Frick, et al.
Nature Computational Science|January 4, 2024
Identifying patterns in amyotrophic lateral sclerosis progression from sparse longitudinal dataDivya Ramamoorthy, Kristen Severson, Soumya Ghosh, et al.
Journal of Speech, Language, and Hearing Research : JSLHR|February 21, 2023
Acoustic Measures of Dysphonia in Amyotrophic Lateral SclerosisMarc F Maffei, Jordan R Green, Olivia Murton, et al.
Frontiers in Digital Health|February 16, 2026
Exploratory analysis of smartphone-based step counts as a digital biomarker for survival in ALS patientsMarcos Matabuena, Marcin Straczkiewicz, Narghes Calcagno, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|April 13, 2026
Development of a machine learning-based survival prediction model for ALS inclusive of the advanced-stage populationDanielle Beaulieu, Kelly Smith, Campbell Ross, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|December 19, 2017
Experience with telemedicine in a multi-disciplinary ALS clinicMarc Van De Rijn, Sabrina Paganoni, Mark Levine-Weinberg, et al.
Drug Discovery Today|September 11, 2014
Neuroprotective agents target molecular mechanisms of disease in ALSYongjin Zhu, Anastasios Fotinos, Lilly L J Mao, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|January 18, 2013
The Combined Assessment of Function and Survival (CAFS): a new endpoint for ALS clinical trialsJames D Berry, Robert Miller, Dan H Moore, et al.
British Journal of Clinical Pharmacology|August 29, 2018
Additional evidence for a therapeutic effect of dextromethorphan/quinidine on bulbar motor function in patients with amyotrophic lateral sclerosis: A quantitative speech analysisJordan R Green, Kristen M Allison, Claire Cordella, et al.
Neurology Research International|March 2, 2026
The Amyotrophic Lateral Sclerosis House Call Program: A Single-Center Experience in the United StatesErica Scirocco, Jennifer Scalia, Benedetta Ugolini, et al.
Pageof 18

Showing results (61-70 of 176) with videos related to

Sort By:
Pageof 18
JAMA Neurology|September 11, 2023
Efficacy and Safety of Ravulizumab, a Complement C5 Inhibitor, in Adults With Amyotrophic Lateral Sclerosis: A Randomized Clinical TrialAngela Genge, Leonard H van den Berg, Glen Frick, et al.
Nature Computational Science|January 4, 2024
Identifying patterns in amyotrophic lateral sclerosis progression from sparse longitudinal dataDivya Ramamoorthy, Kristen Severson, Soumya Ghosh, et al.
Journal of Speech, Language, and Hearing Research : JSLHR|February 21, 2023
Acoustic Measures of Dysphonia in Amyotrophic Lateral SclerosisMarc F Maffei, Jordan R Green, Olivia Murton, et al.
Frontiers in Digital Health|February 16, 2026
Exploratory analysis of smartphone-based step counts as a digital biomarker for survival in ALS patientsMarcos Matabuena, Marcin Straczkiewicz, Narghes Calcagno, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|April 13, 2026
Development of a machine learning-based survival prediction model for ALS inclusive of the advanced-stage populationDanielle Beaulieu, Kelly Smith, Campbell Ross, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|December 19, 2017
Experience with telemedicine in a multi-disciplinary ALS clinicMarc Van De Rijn, Sabrina Paganoni, Mark Levine-Weinberg, et al.
Drug Discovery Today|September 11, 2014
Neuroprotective agents target molecular mechanisms of disease in ALSYongjin Zhu, Anastasios Fotinos, Lilly L J Mao, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|January 18, 2013
The Combined Assessment of Function and Survival (CAFS): a new endpoint for ALS clinical trialsJames D Berry, Robert Miller, Dan H Moore, et al.
British Journal of Clinical Pharmacology|August 29, 2018
Additional evidence for a therapeutic effect of dextromethorphan/quinidine on bulbar motor function in patients with amyotrophic lateral sclerosis: A quantitative speech analysisJordan R Green, Kristen M Allison, Claire Cordella, et al.
Neurology Research International|March 2, 2026
The Amyotrophic Lateral Sclerosis House Call Program: A Single-Center Experience in the United StatesErica Scirocco, Jennifer Scalia, Benedetta Ugolini, et al.
Pageof 18